BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Contract Services Contract Manufacturing

WuXi XDC and Celltrion Collaborate on Comprehensive Antibody-Drug Conjugate (ADC) Services

Under the collaboration, Celltrion will delegate WuXi XDC as primary service provider on each of the integrated projects, from process development to GMP m...

January 24, 2024 | News

Kindeva Drug Delivery Acquires Summit Biosciences, a Nasal Drug Development Specialist

The acquisition of Summit enhances Kindeva’s existing drug-delivery capabilities by adding a new drug-delivery platform, further expanding Kindeva&rs...

January 19, 2024 | News

Vetter Joins German Research-Based Pharma Association (vfa)

Association grants Vetter extraordinary membership vfa recognizes the importance of pharmaceutical service providers in drug development and production ...

January 18, 2024 | News

Eurofins CDMO Alphora Completes New Pilot Scale Biologics Facility

The facilities’ offerings include upstream and downstream development, process design, analytical development, GMP QC testing, GMP Cell-Based Assays,...

January 18, 2024 | News

Thermo Fisher Scientific Introduces First Off-the-Shelf Validated Software for Automated Cell Therapy Manufacturing

To optimize clinical manufacturing processes for innovators developing breakthrough cell therapies, Thermo Fisher Scientific today announced the laun...

January 18, 2024 | News

Bora Pharmaceuticals Expands Globally with $210 Million Acquisition of Upsher-Smith

BioPharma APAC Perspective: Bora's acquisition of Upsher-Smith for $210 million marks a pivotal moment for the pharmaceutical giant. This strategic move n...

January 18, 2024 | News

Charles River Streamlines AAV Vector Manufacturing with Rep/Cap Plasmids Launch

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf Rep/Cap plasmid offering, designed to streamline...

January 17, 2024 | News

WuXi Biologics Secures U.S. Patent for WuXiBody™ Antibody Tech

WuXiBodyTM has been widely adopted globally since its launch in 2018. It can effectively break through the CMC barriers for the development of many bi...

January 17, 2024 | News

WuXi Biologics and BioNTech Partner on Monoclonal Antibody Research Agreement

Under the terms of the agreement, WuXi Biologics leverages its proprietary antibody discovery technology platforms (R in CRDMO) to discover two undisclosed...

January 11, 2024 | News

WuXi AppTec Triples Peptide Capacity, Launches Taixing API Site

WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech an...

January 09, 2024 | News

AGC Biologics to Open New Manufacturing Site in Yokohama, Japan

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced plans to construct...

January 05, 2024 | News

WuXi XDC Partners with IntoCell to Boost ADC Discovery and Development

Under the agreement, IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate (OHPASTM) Linker and novel...

January 03, 2024 | News

AstraZeneca Acquires Gracell, Expanding Cell Therapy Goals in Oncology and Autoimmune Diseases.

AstraZeneca has entered into a definitive agreement to acquire Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL), a global clinical-stage biopharmaceuti...

December 28, 2023 | News

AGC announces strategic expansion of its Biopharmaceutical CDMO capability in Yokohama, Japan, signaling a new era of innovation and growth

This expansion has been selected by the Japanese Ministry of Economy, Trade and Industry (METI) as part of its "Developing biopharmaceutical manufacturin...

December 26, 2023 | News

Stay Connected